Lupin Q2 net profit declines 22.2 pc to Rs 1,155-Cr despite 14 pc revenue growth
Mumbai, Nov 4 ( TNT) : Pharma major Lupin Limited, a Global pharmaceutical leader, on Wednesday reported a 22.2 per cent decline in consolidated net profit at Rs 1,155.3 crore for the second quarter ended September 30, 2026, compared to Rs 1,484.8 crore in the corresponding quarter of the previous financial year.
The company’s revenue from sales increased 14 per cent to Rs 7,785.5 crore during the quarter, against Rs 6,831.4 crore in the year-ago period, according to its unaudited financial results approved by the board of directors.
However, EBITDA declined 10.7 per cent year-on-year to Rs 2,171.2 crore, while the EBITDA margin contracted to 27.9 per cent from 35.6 per cent, a decline of 770 basis points.
Profit before tax (PBT) fell 21.3 per cent to Rs 1,579.6 crore, compared to Rs 2,007 crore in the corresponding quarter last year, Mumbai based pharma company said in a release.
Gross profit increased 15.4 per cent to Rs 5,777.4 crore, with a gross margin of 74.2 per cent.
The company’s research and development expenditure stood at Rs 618.1 crore, accounting for 7.9 per cent of sales during the quarter.
Capital expenditure during the quarter was Rs 223 crore, while net debt stood at minus Rs 3,349 crore as on September 30, indicating a net cash position.
Lupin Managing Director Nilesh Gupta said the company delivered strong performance in the first half of FY27, supported by growth across key markets and sustained profitability.
He expressed confidence in the company’s long-term growth prospects, backed by its product portfolio, continued investments in research and development and commercial capabilities, and focus on disciplined execution.
TNT KM
